EGFR and non-small cell lung carcinoma: In addition, phase IIIb clinical study CTR20211151 is confirming the result of phase II study on METex14-mutated NSCLC, while three ongoing phase II trials, SAVANNAH, SOUND and FLOWERS, as well as three phase IIIB trials, SAFFRON, SACHI and SANOVO, are actively exploring solutions for different types of savolitinib combination regimens against EGFR resistance mechanisms.